AMPH
Amphastar Pharmaceuticals Inc

1,130
Mkt Cap
$1.12B
Volume
5,210.00
52W High
$53.96
52W Low
$20.39
PE Ratio
9.05
AMPH Fundamentals
Price
$24.16
Prev Close
$24.18
Open
$24.01
50D MA
$27.08
Beta
0.63
Avg. Volume
486,657.14
EPS (Annual)
$3.06
P/B
1.48
Rev/Employee
$360,930.47
Loading...
Loading...
News
all
press releases
Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report?
CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.
Zacks·23h ago
News Placeholder
More News
News Placeholder
How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?
CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.
Zacks·9d ago
News Placeholder
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·12d ago
News Placeholder
Down 15.4% in 4 Weeks, Here's Why Amphastar (AMPH) Looks Ripe for a Turnaround
Amphastar (AMPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks·12d ago
News Placeholder
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?
CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.
Zacks·15d ago
News Placeholder
Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?
CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.
Zacks·22d ago
News Placeholder
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?
CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
Zacks·1mo ago
News Placeholder
Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?
CRMD's $300M Melinta buy adds seven therapies, easing reliance on DefenCath sales and bolstering growth in hospital-focused markets.
Zacks·1mo ago
News Placeholder
CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?
CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.
Zacks·1mo ago
News Placeholder
Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?
CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.
Zacks·2mo ago

Latest AMPH News

View

Advertisement|Remove ads.

Advertisement|Remove ads.